Trial in Patients With Relapsed Ovarian Cancer

Sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Study ID
NCT03267589
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The overall objectiv is to obtain preliminary evidence of efficacy of novel agents for the management of relapsed ovarian cancer, and in part 2 efficacy of novel agents compared to the standard of care (SoC).

Key Dates

Start date
May 14, 2018
Status verified
Jul 2025
Primary completion
Oct 19, 2021
Completion
Oct 19, 2021

Study Design

Enrollment
25 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A
    Intervention: MEDI9447 (CD73) + durvalumab
  • Experimental: Cohort B
    Intervention: MEDI0562 (OX40) + durvalumab
  • Experimental: Cohort C
    Intervention: MEDI0562 (OX40) + tremelimumab combination

Primary Outcome Measure

Disease control rate (DCR) [ Time Frame: 16 weeks ]

Related Studies